Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06831344 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate Two Vonoprazan Orally Disintegrating Tablet Formulations Administered Without Water or Mixed With Water and Administered Via a Syringe Relative to the Vonoprazan Tablet in Healthy Participants
A Phase 1 study, sponsored by Phathom Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 25
- Enrollment target
NCT06831344 is a Phase 1 study that has completed, run by Phathom Pharmaceuticals. The registered enrollment target is 25 participants.
The verdict
NCT06831344, a Phase 1 study, has completed, sponsored by Phathom Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 25 participants
- Enrollment target
Study Summary
The primary objective of this study is to assess the bioavailability (BA) of a single oral dose of two vonoprazan orally disintegrating tablet formulations (ODT-1 or ODT-2) administered without water or mixed with water and administered via a syringe relative to the vonoprazan tablet in healthy participants.
Interventions
- DRUG Vonoprazan ODT-1 or ODT-2 without Water
- DRUG Vonoprazan ODT-1 or ODT-2 with Water
- DRUG Vonoprazan (Reference)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2025-02-14 |
| Est. Completion | 2025-04-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06831344
The ClinicalTrials.gov registry entry for NCT06831344 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Phathom Pharmaceuticals, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Vonoprazan ODT-1 or ODT-2 without Water is the first listed.
NCT06831344 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06831344 about?
NCT06831344 is a clinical study titled "A Study to Evaluate Two Vonoprazan Orally Disintegrating Tablet Formulations Administered Without Water or Mixed With Water and Administered Via a Syringe Relative to the Vonoprazan Tablet in Healthy Participants". The primary objective of this study is to assess the bioavailability (BA) of a single oral dose of two vonoprazan orally disintegrating tablet formulations (ODT-1 or ODT-2) administered without water or mixed with water and administered via a syringe relative to the vonoprazan tablet in healthy part...
What is the current status of trial NCT06831344?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 25 participants. The study started on 2025-02-14. Estimated completion is 2025-04-10.
What interventions are being tested in trial NCT06831344?
The interventions under investigation include: Vonoprazan ODT-1 or ODT-2 without Water (DRUG), Vonoprazan ODT-1 or ODT-2 with Water (DRUG), Vonoprazan (Reference) (DRUG).
Who is sponsoring clinical trial NCT06831344?
This trial is sponsored by Phathom Pharmaceuticals, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.